Viewing nowCombinationSitabiang Duo XR Controlled-release Tablets 100/1000 mg
Sitagliptin Hydrochloride Hydrate 113.37mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daehwa Pharmaceutical Co., Ltd.

MFDS item code 202300579 · Approved 2023.02.16 · Insurance code 645605850
Improves blood glucose control in type 2 diabetes mellitus
This medication helps control blood sugar levels in patients with type 2 diabetes. Regularly taking this medication along with diet and exercise therapy can be more effective for blood sugar management. The combined action of sitagliptin and metformin assists in maintaining stable blood sugar levels. Therefore, this medication is used to improve blood sugar control in patients with type 2 diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal, preferably in the evening, and increase the dose gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. Patients not currently treated with metformin: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control is not achieved with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. Patients receiving metformin: The recommended initial total daily dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 100 mg and the current metformin dose. Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start this medicine at a dose of 2 tablets of 50/1000 mg extended-release tablets once daily. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When used concomitantly with a sulfonylurea or insulin, reduction of the sulfonylurea or insulin dose may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.
This medication is a combination of sitagliptin and metformin, used for diabetes treatment. Firstly, the sitagliptin component can cause rare but serious allergic reactions. These reactions may include anaphylaxis, angioedema, and serious skin disorders, so if skin rashes, difficulty breathing, swelling of the face or neck occur within 3 months after taking the medication, stop taking it immediately and consult a doctor. Additionally, sitagliptin can cause pancreatitis, which is inflammation of the pancreas, so if sudden abdominal pain, nausea, vomiting, or other symptoms appear, stop taking the medication immediately and seek medical attention. The metformin component can cause a rare side effect known as lactic acidosis, which is a very dangerous condition that requires prompt treatment. Therefore, this medication should not be taken by patients with impaired kidney function or those with certain conditions such as severe infections, dehydration, or heart failure. This medication should not be administered to patients with moderately impaired kidney function or worse, patients with acute heart failure, patients receiving radiological contrast agents, type 1 diabetes patients, or women who are pregnant or breastfeeding. Moreover, caution should be exercised while taking this medication in cases of irregular meals, vigorous exercise, and interactions with certain drugs, as it contains Red 40, which may cause allergic reactions in sensitive individuals. During treatment, gastrointestinal disturbances, hypoglycemia, or skin rashes may occur, so consult a doctor if symptoms are severe or concerning. Finally, temporarily stopping the medication before and after surgery or in cases of severe infections or trauma is required, and it can be resumed once the condition stabilizes.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air and moisture. The storage temperature should be maintained between 1 degree and 30 degrees Celsius at room temperature. This will help preserve the medication's effectiveness for a longer period.
Light blue, bilaterally convex oval-shaped controlled-release film-coated tablets
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 113.37mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daehwa Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.